share_log

CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024

CervoMedは、AscenD-LB第2a相試験のバイオマーカーデータと、Tau媒介性疾患におけるNeflamapimodの潜在的可能性を支持するプレクリニカルデータの発表をAD/PD 2024で行うことを発表しました。

Benzinga ·  03/05 08:01

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP)

-Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR Sum of Boxes (CDR-SB)

- Scientific collaborators from University College London (UCL) present data demonstrating neflamapimod improves axonal transport in a transgenic mouse model of frontotemporal dementia (FTD)

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする